We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDT Expands Agreement With Merit to Offer ViaVerte: Stock to Gain?
Read MoreHide Full Article
Key Takeaways
Medtronic signs a distribution deal with Merit to offer the ViaVerte BVNA system for chronic back pain.
The FDA-cleared system adds a minimally invasive, implant-free option to MDT's pain therapies portfolio.
Rising demand for BVNA and a growing global market support expansion of MDT's pain intervention offerings.
Medtronic plc (MDT - Free Report) recently entered into a distribution agreement with Merit Medical Systems, Inc. (MMSI) to offer FDA-cleared ViaVerte — a minimally invasive and implant free basivertebral nerve ablation (BVNA) system. ViaVerte BNVA expands the company’s world-leading pain interventions portfolio and gives patients and their physicians meaningful option for lasting relief.
This agreement underscores Medtronic’s ongoing momentum in strategic dealmaking, strengthening its leadership in key core franchises.
MDT Stock’s Likely Trend Following the News
Yesterday, MDT’s shares lost 0.7% following the announcement.
Medtronics’ portfolio of pain therapies includes spinal cord stimulation, vertebral augmentation, nerve ablation, bone tumor ablation and targeted drug delivery. The addition of an advanced steerable solution for BVNA expands this portfolio to directly meet the growing demand for this expanded therapy option. We expect the news to boost market sentiment toward MDT stock in the upcoming days.
Medtronic presently has a market capitalization of $110.62 billion. The company’s earnings yield of 6.46% compares with the industry’s 2.64%. It delivered a trailing four-quarter average earnings surprise of 2.76%.
About MDT’s ViaVerte BVNA System
The ViaVerte BVNA system offers patients a minimally invasive, same day outpatient procedure. It is the first and only BVNA system with a physician-controlled, steerable mechanism that enables precise targeting of the basivertebral nerve for the treatment of chronic vertebrogenic lower back pain. The system is expected to be available later in 2026.
More on Medtronic’s Partnership With Merit
This exclusive agreement expands Medtronic’s comprehensive pain interventions portfolio and increases treatment options for patients living with chronic pain. Merit currently supplies Medtronic's Kyphon Xpander Inflation Syringes used in balloon kyphoplasty procedures and Kyphon KyphoFlex unipedicular steerable balloon catheter for treating vertebral compression fractures.
Image Source: Zacks Investment Research
Industry Prospects Favor MDT
According to the American Chronic Pain Association (“ACPA”), an estimated one in three Americans suffers from some type of chronic pain. BVNA is a rapidly growing therapy option for patients suffering from chronic low-back pain caused by damaged vertebral endplates. As per Dataintelo’s latest research, the global BNVA systems market size reached $650 million in 2024 and is experiencing a robust compound annual growth rate (CAGR) of 10.8%, expected to reach $1.56 billion by 2033.
Another Recent Development by MDT
On Monday, Medtronic received Food and Drug Administration (FDA) approval for an expanded indication for its OmniaSecure defibrillation lead. It is approved for placement in the left bundle branch (LBB) area, in which the lead can be used for conduction system pacing (CSP) to closely mimic the heart's natural physiology. Patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a novel therapy that combines CSP with left-ventricular pacing to further improve patient outcomes.
MDT Stock Price Performance
Over the past year, MDT’s shares have lost 1.8% compared with the industry’s 20.5% decline.
Medtronic’s Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, which outpaced the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
MDT Expands Agreement With Merit to Offer ViaVerte: Stock to Gain?
Key Takeaways
Medtronic plc (MDT - Free Report) recently entered into a distribution agreement with Merit Medical Systems, Inc. (MMSI) to offer FDA-cleared ViaVerte — a minimally invasive and implant free basivertebral nerve ablation (BVNA) system. ViaVerte BNVA expands the company’s world-leading pain interventions portfolio and gives patients and their physicians meaningful option for lasting relief.
This agreement underscores Medtronic’s ongoing momentum in strategic dealmaking, strengthening its leadership in key core franchises.
MDT Stock’s Likely Trend Following the News
Yesterday, MDT’s shares lost 0.7% following the announcement.
Medtronics’ portfolio of pain therapies includes spinal cord stimulation, vertebral augmentation, nerve ablation, bone tumor ablation and targeted drug delivery. The addition of an advanced steerable solution for BVNA expands this portfolio to directly meet the growing demand for this expanded therapy option. We expect the news to boost market sentiment toward MDT stock in the upcoming days.
Medtronic presently has a market capitalization of $110.62 billion. The company’s earnings yield of 6.46% compares with the industry’s 2.64%. It delivered a trailing four-quarter average earnings surprise of 2.76%.
About MDT’s ViaVerte BVNA System
The ViaVerte BVNA system offers patients a minimally invasive, same day outpatient procedure. It is the first and only BVNA system with a physician-controlled, steerable mechanism that enables precise targeting of the basivertebral nerve for the treatment of chronic vertebrogenic lower back pain. The system is expected to be available later in 2026.
More on Medtronic’s Partnership With Merit
This exclusive agreement expands Medtronic’s comprehensive pain interventions portfolio and increases treatment options for patients living with chronic pain. Merit currently supplies Medtronic's Kyphon Xpander Inflation Syringes used in balloon kyphoplasty procedures and Kyphon KyphoFlex unipedicular steerable balloon catheter for treating vertebral compression fractures.
Image Source: Zacks Investment Research
Industry Prospects Favor MDT
According to the American Chronic Pain Association (“ACPA”), an estimated one in three Americans suffers from some type of chronic pain. BVNA is a rapidly growing therapy option for patients suffering from chronic low-back pain caused by damaged vertebral endplates. As per Dataintelo’s latest research, the global BNVA systems market size reached $650 million in 2024 and is experiencing a robust compound annual growth rate (CAGR) of 10.8%, expected to reach $1.56 billion by 2033.
Another Recent Development by MDT
On Monday, Medtronic received Food and Drug Administration (FDA) approval for an expanded indication for its OmniaSecure defibrillation lead. It is approved for placement in the left bundle branch (LBB) area, in which the lead can be used for conduction system pacing (CSP) to closely mimic the heart's natural physiology. Patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a novel therapy that combines CSP with left-ventricular pacing to further improve patient outcomes.
MDT Stock Price Performance
Over the past year, MDT’s shares have lost 1.8% compared with the industry’s 20.5% decline.
Medtronic’s Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, which outpaced the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.3%.